Table 1
EtanerceptInfliximabAdalimumabRituximabTocilizumabCertolizumab
Primary Analysis
 Follow-up (yrs)15314882913071591019631685
 Infections (single failure)85247270937213764
 Incidence per 100 patient years (95% CI)5.56 (5.20, 5.95)5.35 (4.89, 5.85)5.42 (5.04, 5.84)6.29 (5.69, 6.97)6.98 (5.90, 8.25)3.80 (2.97, 4.85)
 Serious Infection Hazard Ratio (95% CI)Ref0.94 (0.84, 1.06)0.97 (0.88, 1.07) 1.15 (1.01, 1.30) 1.22 (1.02, 1.47) 0.65 (0.51, 0.84)
 Adjusted HR (95% CI)Ref0.87 (0.77, 1.00)0.98 (0.88, 1.08)0.91 (0.80, 1.04)1.17 (0.93, 1.47) 0.69 (0.52, 0.92)
Adjusted Hazard Ratio By Infection Class (95% CI)
 Sepsis/BacteraemiaRef0.83 (0.41, 1.66)1.04 (0.57, 1.91) 2.08 (1.14, 3.80) 1.83 (0.63, 5.35)1.03 (0.24, 4.41)
 Respiratory InfectionRef1.16 (0.96, 1.39) 1.23 (1.04, 1.45) 1.03 (0.83, 1.28) 1.61 (1.15, 2.25) 0.96 (0.63, 1.46)
 Skin InfectionRef0.84 (0.66, 1.06) 0.65 (0.52, 0.82) 0.54 (0.39, 0.75) 0.71 (0.40, 1.24) 0.27 (0.11, 0.67)
 Gastrointestinal InfectionRef0.95 (0.66, 1.38)0.77 (0.54, 1.11)0.93 (0.61, 1.42)1.45 (0.72, 2.90)0.51 (0.16, 1.63)
 Bone/Joint InfectionRef 0.56 (0.38, 0.83) 0.80 (0.58, 1.09)0.67 (0.43, 1.02)0.46 (0.17, 1.27)0.73 (0.32, 1.68)
 Genitourinary InfectionRef0.74 (0.50, 1.07)1.18 (0.87, 1.59)1.15 (0.79, 1.68)0.67 (0.27, 1.66)0.55 (0.20, 1.52)
 OtherRef 0.54 (0.31, 0.91) 1.08 (0.74, 1.58)0.72 (0.41, 1.29)1.15 (0.49, 2.67)0.50 (0.16, 1.60)